On February 1, 2022 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, reported a collaboration with Rutgers, The State University of New Jersey (Press release, NexImmune, FEB 1, 2022, View Source [SID1234607582]). The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers. Dr. Steven K. Libutti, Director of Rutgers Cancer Institute of New Jersey, Vice Chancellor of Cancer Programs, Rutgers Biomedical and Health Sciences, and Senior Vice President of Oncology Services, RWJBarnabas Health, will be the principal investigator.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Neuroendocrine tumors are being diagnosed with increasing frequency in the United States and represent a large unmet medical need," said Dr. Jerry Zeldis, NexImmune’s Executive Vice President, R&D. "With Dr. Libutti, we hope to discover and develop novel treatments utilizing our AIM ACT platform that may improve the timely and effective treatment of neuroendocrine neoplasia."

"HHLA2 and B7x are expressed by a number of tumors and can modulate cancer development and progression by inhibiting T cell function. Our work with NexImmune allows us to utilize a novel immunotherapy platform with the goal of improving survival using better and safer treatments in patients with few treatment options," stated Dr. Libutti.